MacroGenics Doses First Patient in Phase 1 Trial of Cancer Drug MGC030
MacroGenics, Inc. (MGNX) has administered the initial dose to the first patient in an open-label Phase 1 clinical trial evaluating MGC030, an experimental treatment for advanced solid tumors. MGC030 is a first-in-class antibody-drug conjugate designed to target an undisclosed antigen for which no approved treatments currently exist. The dose-escalation portion of the study is expected to enroll up to 54 participants.
The initiation of this study marks the third antibody-drug conjugate candidate entering active clinical development for MacroGenics. The drug utilizes the Synaffix SYNtecan E payload, which belongs to the topoisomerase I payload class. Advancing a novel therapy against an unvalidated target offers potential pipeline growth for the company as it expands its focus on antibody-drug conjugate technologies. Shares of MacroGenics rose 1.96% to $3.375 following the announcement.
Investors and clinical observers will monitor the trial as it progresses through dose escalation and expansion cohorts. Key near-term catalysts for the program include initial readouts on safety, pharmacokinetics, and any early signals of antitumor activity in treated patients.
Key points
- MacroGenics, Inc. (MGNX) dosed the first patient in a Phase 1 trial for its experimental cancer treatment, MGC030.
- The open-label study will include dose escalation and plans to enroll up to 54 participants with advanced solid tumors.
- MGC030 is a first-in-class antibody-drug conjugate targeting an undisclosed antigen using a Synaffix SYNtecan E payload.
- The trial represents the third antibody-drug conjugate candidate that MacroGenics has moved into active clinical development.
- Future study milestones will focus on evaluating the drug's safety, pharmacokinetics, and initial antitumor response.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is MGC030 and what condition does it target?
MGC030 is a first-in-class antibody-drug conjugate developed by MacroGenics, Inc. to treat patients with advanced solid tumors. It utilizes a Synaffix SYNtecan E payload and targets an undisclosed antigen with no existing approved therapies.
How many patients will participate in the Phase 1 trial of MGC030?
The Phase 1 open-label study includes a dose-escalation design that is expected to enroll up to 54 participants.
What are the key upcoming catalysts for the MGC030 study?
Key future milestones include readouts on initial safety, pharmacokinetics, and early signs of antitumor efficacy from the study's dose-escalation and expansion cohorts.